# A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs

> **NCT06232564** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Imperial College London** · enrollment: 20 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **COMBINATION_PRODUCT:** Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy

## Key facts

- **NCT ID:** NCT06232564
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-08
- **Primary completion:** 2027-10-15
- **Final completion:** 2027-10-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06232564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06232564, "A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06232564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*